Objective: Aortic valve stenosis (AS) is becoming more prevalent in the elderly population. The aim of this study was to determine if patients aged ≥80 years are at a higher risk of aortic valve replacement (AVR) for AS, with or without coronary artery bypass grafting (CABG), compared to their younger counterparts.
Introduction
Life expectancy is increasing in many countries, and more than 10 million people aged ≥80 years live in Japan. The life expectancy of Japanese 80-year-old men and women is reported to be 8.9 and 11.8 years, respectively. In this elderly patient population, the most common structural heart disease is degenerative calcified aortic stenosis (AS) 1) . A recent study showed that the prevalence of AS in the octogenarian population is 9.8% 2) .
Current guidelines recommend surgical aortic valve replacement (AVR) in patients with severe AS with a low to intermediate surgical risk, or transcatheter aortic valve implantation (TAVI) as a reasonable alternative to surgical AVR in those at high risk, particularly elderly high-risk patients 3) 4) .
A randomized, controlled trial in elderly AS patients at high surgical risk demonstrated that TAVI is non-inferior to AVR, and the 5-year survival is similar 5) . However, a final decision between AVR and TAVI, particularly in octogenarians, should be made by the Heart Team after careful individual evaluation 3) . Therefore, there is an increasing interest in the evaluation of early and late outcomes after AVR in elderly patients.
The aim of this study was to determine if patients aged ≥80 years are at a higher risk of AVR for AS compared to their younger counterparts, by examining the risk factors for early mortality and morbidity, postoperative prolonged length of hospital stay (PLOS), non-home discharge, and late mortality.
Materials and Methods
Between August 2002 and December 2016, 593 consecutive patients underwent AVR for AS at Juntendo University Hospital, including 203 patients who required concomitant coronary artery bypass grafting (CABG). Patients were excluded from this study if they required concomitant mitral and/or tricuspid valve surgery (n = 180). Patients were classified into four groups by years of age: Pt < 60, Pt 60-69, Pt 70-79, and Pt ≥80. This study was approved by the Medical Ethics Committee of Juntendo University. Outcome measures included early mortality, postoperative complications (stroke, respiratory failure, renal failure, gastrointestinal complication, and systemic infection), PLOS (more than 15 days after surgery), non-home discharge, and long-term mortality. Early mortality after AVR was defined as death within 30 days of surgery or as death at any time before discharge from the hospital. Renal failure was defined as a new requirement for postoperative dialysis. Respiratory failure was defined as prolonged postoperative ventilator support (≥24 hours) or need for reintubation or tracheostomy. Stroke was defined as a new permanent postoperative neurological event.
One patient was lost to follow-up at one year after surgery, and this patient was excluded from the analysis of late survival. Completeness of follow-up of this study was 99.8%, and the mean follow-up period was 5.5 years.
All operative procedures were carried out through a full or partial sternotomy using cardiopulmonary bypass with systemic normothermia or mild hypothermia. Myocardial protection was achieved with a combined antegrade and retrograde cold blood cardioplegia. The aortic valve prostheses used in this study included 460 biological valves (Carpentier-Edwards, n = 307; Trifecta, n = 98; Mosaic, n = 33; Mitroflow, n = 22) and 133 mechanical valves (OnX, n = 55; St. Jude Medical, n = 48; ATS, n = 26; CarboMedics, n = 3; Bicarbon, n = 1). Concomitant CABG was performed in 34% of the patients (n = 203). Anticoagulation with warfarin was commenced 1 to 2 days after the operation for patients who received a mechanical prosthesis.
Statistical analysis
Continuous variables were reported as the mean ± standard deviation and were compared between groups using the Student t-test or one-way analysis of variance (ANOVA). Categorical variables were given as percentages and were compared between groups using a chi-square test or Fisherʼs exact test. Kaplan-Meier curves and the log-rank test were used for long-term survival analysis. A p-value < 0.05 was considered statistically significant. Multivariable analysis using multiple logistic regression was performed to identify the independent predictors of early mortality and morbidity that are presented as odds ratio (OR), 95% confidence interval (CI), and p-value. A Cox proportional hazards multivariable model was used to identify the predictors of long-term mortality that are presented as hazard ratio (HR), 95%CI, and p-value. Statistical analysis was performed using SPSS version 18.0 software (IBM, Armonk, New York).
Results
The preoperative characteristics for the four age groups are shown in Table- recent myocardial infarction, pulmonary hypertension, urgency, weight of the intervention, and surgery on the thoracic aorta. The operative characteristics for all patients and for each age group are demonstrated in Table- 2. Bioprosthetic valves were used most often in the elderly patients. Concomitant CABG was performed more frequently in the older age groups. Although the aortic cross-clamp time was not different among the groups, the trend towards a shorter cardiopulmonary bypass time was observed in the older patient population.
In-hospital outcomes after AVR are presented in Table-3 . Surprisingly, there was no statistical difference in mortality or morbidity among the age groups. However, the Pt ≥80 group had significantly higher incidences of postoperative PLOS and non-home discharge. Early mortality among all the patients was 3.0%, with no statistically significant difference among the age groups ( On multivariable analysis, NYHA class III and IV and hemodialysis were identified as independent predictors of early mortality (Table-4 , Model A). When EuroSCORE II was entered into the multivariable analysis, instead of the individual predictors, EuroSCORE II remained an independent risk factor of early mortality.
A total of 77 patients (13%) developed at least one major complication, but there were no differences Machida, in any of the individual complications or composite complications among the age groups (Table-3 ). Multivariable analysis revealed that NYHA class III and IV and diabetes mellitus were associated with increased postoperative composite complications (Table-4 , Model A). In Model B, which included EuroSCORE II, EuroSCORE II remained an independent risk factor of composite complications (Table-4 
, Model B).
We attempted to identify the risk factors that predict PLOS (defined as > 15 days after AVR). The incidence of PLOS was significantly higher in the Pt ≥80 group than in the younger patient groups (Table-3 ). Multivariable analysis identified advanced age, hemodialysis, NYHA class III and IV, CABG, and atrial fibrillation as independent predictors of PLOS (Table-5 , Model A). In Model B, EuroSCORE II was found to be an independent risk factor of PLOS (Table-5 
A total of 50 out of 126 patients (39.6%) aged ≥80 years required PLOS, and the major reasons were postoperative delayed rehabilitation (n = 37, 74%) and paroxysmal atrial fibrillation (n = 16, 32%).
The Pt ≥80 group had a significantly higher incidence of non-home discharge when compared with the younger age groups (Table-3 Table-5 ). Therefore, the Pt ≥80 group had a higher incidence of increased hospital resource utilization, including PLOS and non-home discharge. A total of 24 out of 126 patients (19%) aged ≥80 years needed non-home discharge, and the major reason was further rehabilitation (n = 12, 50%). The mean follow-up time was 5.3 ± 3.6 years. Five-year survival rates for the Pt < 60, Pt 60-69, Pt 70-79, and Pt ≥80 groups were 96.1%, 86.3%, 89.8%, and 78.9%, respectively (Figure-1 ). There was a statistically significant difference in survival among the age groups (p = 0.01) ( Table-6 ). The independent predictors for long-term mortality were advanced age, hemodialysis, and redo surgery in Model A, and EuroSCORE II in Model B.
Discussion
With an increasing number of elderly patients with AS being referred for surgery, particularly in those aged ≥80, evaluation of the surgical results in these elderly patients has become a major concern 7)-16) . In recent years, TAVI has emerged as a less invasive alternative to AVR for elderly highrisk AS patients, particularly in octogenarians, but controversy exists about which patients ≥80 years of age may actually benefit from TAVI compared with AVR 17) 18) . Therefore, the aim of this study was to determine if patients aged ≥80 years are at a higher risk of AVR for AS compared to their younger counterparts.
Early mortality
Our study demonstrates that good AVR results in patients aged ≥80 years, with similar early mortality and morbidity compared to their younger counterparts, can be can be expected (Table-3 ). The long-term results in patients aged ≥80 years are also satisfactory with greater than 70% survival at 5 years after AVR (Figure-1) . Previous studies, from the mid-1990ʼs and earlier, which examined the results of AVR with or without CABG, reported early mortality between 8.5% and 12.8% in patients aged ≥80 years 19) 20) . However, more recent studies have shown an improvement in early mortality between 3.7% and 7.2% 21)- 24) . Therefore, the early mortality of 3.1% in our Pt ≥80 group is consistent with recent reports, including larger series. In our experience, the early mortality in the Pt ≥80 group decreased from 5.1% between 2002 and 2010 to 2.2% between 2011 and 2016.
The recent improvements of operative early mortality after AVR, particularly in elderly patients, may be related to advances in perioperative management and continued refinements, including surgical techniques, cardiac anesthesia, meticulous myocardial protection, and postoperative management and rehabilitation. Another possible explanation for the reduction in early mortality could be improving patient selection for AVR by the cardiac surgeon and cardiologist. Our study showed that the Pt ≥80 group had very similar early mortality (3.1%) of AVR when compared with their younger counterparts ( Table-3 ). Similar excellent results have recently been reported in studies analyzing outcomes of AVR in octogenarians and older, where the early mortality rates were between 2.7% and 3.2% 8) 25) . In our study, advanced NYHA class, hemodialysis, and Euro-SCORE II ≧ 3% were identified as independent predictors for early mortality after AVR (Table-4 ). However, advanced age was not an independent risk predictor of early mortality. Both Abel et al. 12) and Thourani et al. 7) reported similar results.
Postoperative complication
In our study, an age ≥80 years was not a statistically significant risk factor for major postoperative complications when compared with younger patients. However, a trend towards an increased rate of composite complications after AVR in patients aged ≥80 years was observed (Table-3) . Thourani et al. 7) showed similar morbidity outcomes in octogenarians undergoing AVR; they did not show a statistically significant increase in major adverse complications, except for prolonged ventilator dependence, in octogenarians compared with younger patients. In our study, the respiratory failure rate was higher in the Pt ≥80 group (10.3%) compared with the younger age groups (3.8% to 7.5%), but the difference was not statistically significant (Table-3 ).
PLOS and non-home discharge
PLOS and non-home discharge, as measures of postoperative recovery in elderly patients, are important when evaluating the outcomes of AVR. Our study demonstrates that an age ≥80 years is an independent predictor for both PLOS (p = 0.002) and non-home discharge (p = 0.001) ( Table-5 ). The PLOS rate in the Pt ≥80 group was 1.3 to 1.9 times higher than in the younger age groups (Table-3 ). The non-home discharge rate in the Pt ≥80 group was 1.8 to 3.6 times higher than in the younger age groups (Table-3 ). Another interesting finding was that EuroSCORE II ≥3% is an independent predictor of both PLOS and non-home discharge ( Table-5 ). Stratification of the Pt ≥80 group by EuroSCORE II revealed that a high-risk of slow recovery was seen in patients with EuroSCORE II ≥3% (PLOS rate: 50%, non-home discharge rate: 25%) when compared to those with EuroSCORE II < 3% (PLOS rate: 25%, non-home discharge rate: 11%). Slow recovery may have an impact on hospital resource utilization and quality of life, and therefore less invasive procedures, such as TAVI or sutureless aortic valve prosthesis, may be attractive alternatives to improve the postoperative recovery in these high-risk elderly patients. However, in the above-mentioned less-invasive treatment modality, long-term valve durability has not yet been proven. The other useful strategies to improve postoperative recovery are preoperative aggressive rehabilitation 26) to improve physical function, particularly in frail elderly patients, and prophylactic administration of beta-blockers 27) to prevent postoperative atrial fibrillation.
Long-term mortality
As expected, the Pt ≥80 group showed the worst survival when compared with the other age groups (Figure-1 ). However, a survival at 5 years of 78% for the Pt ≥80 group was very satisfactory. Several recent studies of AVR in patients aged ≥80 years have also reported a 5-year survival rate of more than 70% 24) 28)-30) . Therefore, contemporary AVR in patients aged ≥80 years is associated with a very good late survival. In addition, the 5-year post-AVR survival rate in patients aged ≥80 years was reported to be not inferior to the age-matched general population. Filsoufi et al. 8) from the United
States reported a 5-year survival rate of 63.8% for patients aged ≥80 years who underwent AVR, and the late survival was similar to the expected survival of the age-and gender-matched general population. These results provide evidence of the efficacy of AVR, even in very elderly patients.
Limitations
The major limitation of our study is that it was a single-center retrospective trial with a relatively small sample size. Therefore, the results may not be representative of other institutions. A larger validation study is necessary to confirm our results, especially for elderly patients who have an increasing clinical need for reliable contemporary surgical methods. A second limitation is that the follow-up data regarding the reasons for late death are incomplete, because we could not provide precise information regarding the causes. Asimakopoulos et al. 30) found that late deaths tended to be associated with noncardiac diseases, including malignancy, stroke, and pneumonia in patients aged ≥80 years who underwent AVR. A third limitation is the potential selection bias of patients referred for surgery, particularly in very elderly patients. We do not have information on how many patients who were initially referred for surgery were ultimately denied the surgery (nor the reasons for the denial). Therefore, quantifying the number of patients who were considered inoperable but continued with medical management or were referred for TAVI is not possible.
In conclusion, we demonstrated that AVR in patients ≥80 years can be performed with low mortality and morbidity, and excellent long-term survival. Therefore, advanced age alone should not be considered a contraindication to AVR.
